We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

68 hedge funds and large institutions have $612M invested in ArriVent BioPharma in 2024 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,167% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 3

700% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 2

51% more capital invested

Capital invested by funds: $404M → $612M (+$208M)

26% more funds holding

Funds holding: 54 → 68 (+14)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

12.48% more ownership

Funds ownership: 64.66% → 77.13% (+12%)

Holders
68
Holders Change
+14
Holders Change %
+25.93%
% of All Funds
0.98%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
16
Increased
38
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$28.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$15.8M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$8.22M
4
State Street
State Street
Massachusetts
+$7.34M
5
Millennium Management
Millennium Management
New York
+$4.64M

Top Sellers

Rank Fund Capital Flow
1
AA
AlphaCentric Advisors
Puerto Rico
-$1.61M
2
HLAM
Hidden Lake Asset Management
New York
-$689K
3
Walleye Capital
Walleye Capital
New York
-$464K
4
Jane Street
Jane Street
New York
-$107K
5
TRCT
Tower Research Capital (TRC)
New York
-$29.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
N
26
Nuveen
North Carolina
$1.04M +$606K +26,712 +152%
Bank of America
27
Bank of America
North Carolina
$1.02M +$839K +36,964 +587%
Barclays
28
Barclays
United Kingdom
$976K +$866K +38,132 +1,125%
RhumbLine Advisers
29
RhumbLine Advisers
Massachusetts
$790K +$475K +20,914 +165%
AllianceBernstein
30
AllianceBernstein
Tennessee
$663K +$640K +28,200 New
AA
31
ALPS Advisors
Colorado
$645K +$29.4K +1,294 +5%
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$516K +$123K +5,397 +33%
Citigroup
33
Citigroup
New York
$479K +$414K +18,237 +843%
UBS Group
34
UBS Group
Switzerland
$438K +$151K +6,651 +55%
MIM
35
MetLife Investment Management
New Jersey
$384K +$233K +10,269 +169%
Mirae Asset Global ETFs Holdings
36
Mirae Asset Global ETFs Holdings
Hong Kong
$371K +$248K +10,906 +223%
Deutsche Bank
37
Deutsche Bank
Germany
$360K +$348K +15,331 New
CF
38
Corebridge Financial
Texas
$354K +$222K +9,783 +185%
AA
39
AlphaCentric Advisors
Puerto Rico
$353K -$1.61M -71,000 -83%
JP Morgan Chase
40
JP Morgan Chase
New York
$292K +$183K +8,050 +183%
SG Americas Securities
41
SG Americas Securities
New York
$280K +$271K +11,927 New
Qube Research & Technologies (QRT)
42
Qube Research & Technologies (QRT)
United Kingdom
$267K +$258K +11,354 New
Jane Street
43
Jane Street
New York
$250K -$107K -4,707 -31%
Wells Fargo
44
Wells Fargo
California
$243K +$153K +6,751 +187%
Manulife (Manufacturers Life Insurance)
45
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$240K +$232K +10,234 New
Rafferty Asset Management
46
Rafferty Asset Management
New York
$224K +$216K +9,536 New
T. Rowe Price Associates
47
T. Rowe Price Associates
Maryland
$220K +$212K +9,345 New
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
$206K +$199K +8,775 New
AQR Capital Management
49
AQR Capital Management
Connecticut
$203K +$197K +8,657 New
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$136K +$65.8K +2,900 +101%
1
2
3

AVBP Hedge Fund Activity: Q3 2024 in Review

68 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q3 2024, worth a combined $612M — up 51% from $404M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVBP positions and 2 closed out — a net gain of 14 holders — while 38 added to existing stakes and 3 trimmed.

The largest buyer was BlackRock, adding an estimated $28.8M. The largest seller was AlphaCentric Advisors, cutting an estimated $1.61M.

  • 68 institutional investors held ArriVent BioPharma (AVBP) as of Q3 2024, up from 54 in Q2 2024.
  • Funds reported $612M of ArriVent BioPharma stock for Q3 2024, up 51% quarter-over-quarter.
  • 16 funds opened new ArriVent BioPharma positions in Q3 2024 and 2 closed out, a net change of +14 holders.
  • The largest ArriVent BioPharma buyer in Q3 2024 was BlackRock, an estimated $28.8M added.
  • The largest ArriVent BioPharma seller in Q3 2024 was AlphaCentric Advisors, an estimated $1.61M sold.

Based on aggregated 13F filings for Q3 2024.